Recombinant human erythropoietin (rHuEpo) has been used successfully in the treatment of cancer-related anemia. Clinical observations with several patients with multiple-myeloma treated with rHuEpo has shown, in addition to the improved quality of life, a longer survival than expected, considering the poor prognostic features of these patients. Based on these observations, we evaluated the pote...

The complete peripheral blood count analysis including laboratory screening tests of haemostasis and coagulation should be done in every patient before surgery, in order to detect specific abnormalities for primary or secundary haematologic disorder. These abnormalities might be very important course of perioperative and postoperative complications. Anaemia is the most frequent haematologic abn...

6. Peschle C, Marmont AM, Marone G, Genovesi A, Sasso G, Condorelli M: Pure red cell aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin. Br I Haematol 30:405, 1975 7. Krantz SB: Studies on red cell aplasia. III. Treatment with horse antihuman thymocyte gamma globulin. Blood 39:347, 1972 8. Marmont AM, Peschle C, Sanguineti M, Condorelli M: Pure red cell aplasia (PRCA): Respo...

A method for conditioning data used in the measurement of the modulation transfer function (MTF) is discussed. This method is based upon imposing the constraint that the edge spread function (ESF) is monotonic. The advantages of this technique, when applicable, are demonstrated with simulated examples for which the true MTF is known. The application of this technique in the measurement of the M...

T HE ANEMIA of uremia is the result of hemolysis and depression of red cell formation.1 Its aregenerative component has attracted considerable interest after Jacobson et al.2’54 reported the absence of ervthropoietin in the plasma of nephrectomized rats subjected to hypoxia, acute hemorrhage or cobalt administration. The same stimuli applied to rats made anuric by ureteral ligation produced ery...

Recombinant human erythropoietin (EPO) is the main therapeutic glycoprotein for treatment of anemia in cancer and kidney patients. The in-vivo activity EPO carbohydrate-dependent with number sialic acid residues regulating its circulatory half-life. carries three N-glycans thus obtaining pure glycoforms provides a major challenge. We have developed robust reproducible chemoenzymatic approach to...

Anemia in children with cancer is not an uncommon complication and is usually multifactorial in etiology. In numerous trials in adult cancer patients, treatment with recombinant erythropoietin has been shown to increase hemoglobin levels, reduce red blood cell transfusion requirements, and improve quality of life. Much less has been published of its use in the prevention or treatment of cancer-...

One of the primary goals in the perioperative care of orthopaedic patients undergoing surgery is the avoidance of allogeneic transfusion. There are a number of ways to lessen blood loss during surgical intervention including regional hypotensive anesthesia, careful and atraumatic surgical technique, and coagulation of bleeding surfaces. Achieving coagulation is difficult in spinal and arthropla...

Recombinant human erythropoietin (rhEpo) has proven to be remarkably safe and effective for treatment of anemias, primarily those secondary to renal disease and malignancy. Despite the worldwide use of rhEpo, concerns about its cost, the need for frequent parenteral administration, and the development of anti-Epo antibodies have prompted development of improved agents to stimulate erythropoiesi...